Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 4:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 2,339 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pharmacokinetics and Pharmacodynamics Clear all
Recruiting Phase 1 Interventional

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

NCT06271252
View directory record Official record
Conditions
Neoplasms, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Hemostatic Disorders, Vascular Diseases, Cardiovascular Diseases, Paraproteinemias, Blood Protein Disorders, Hematologic Diseases, Hemorrhagic Disorders, Lymphoproliferative Disorders, Immunoproliferative Disorders, Immune System Diseases, Multiple Myeloma
Interventions
OriCAR-017
Drug
Lead sponsor
OriCell Therapeutics Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 16, 2026, 4:40 PM EDT
Terminated Phase 1 Interventional

Dose-escalation Study of Lupartumab Amadotin (BAY1129980)

NCT02134197
View directory record Official record
Conditions
Neoplasms
Interventions
Lupartumab Amadotin (BAY1129980)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
15
States / cities
La Jolla, California • Stanford, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 2 Interventional

Study of an Extended-Release, Crystalline Formulation of Recombinant Human Growth Hormone (ALTU-238) in Growth Hormone Deficient Adults to Determine Pharmacokinetics, Pharmacodynamics, and Drug Safety

NCT00297713
View directory record Official record
Conditions
Adult Growth Hormone Deficiency
Interventions
ALTU-238
Drug
Lead sponsor
Altus Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
3
States / cities
Louisville, Kentucky • Galveston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2006 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects

NCT05384262
View directory record Official record
Conditions
Dyslipidemia
Interventions
AZD0780, Placebo, Rosuvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia

NCT03525886
View directory record Official record
Conditions
CAH - Congenital Adrenal Hyperplasia
Interventions
NBI-74788
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Aurora, Colorado • Indianapolis, Indiana • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

SAD Study of IA-14069

NCT05317741
View directory record Official record
Conditions
Healthy
Interventions
IA-14069, Placebo
Drug
Lead sponsor
ILAb Co., Ltd.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 16, 2026, 4:40 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)

NCT05574010
View directory record Official record
Conditions
Celiac Disease
Interventions
Cohort 1 in Part A, Cohort 2 in Part A, Placebo: Group 1 in Part B and Part C, Group 2 in Part B and Part C, Group 3 in Part B and Part C, Group 4 in Part B and Part C
Drug · Other
Lead sponsor
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
23
States / cities
Birmingham, Alabama • Anaheim, California • St. Petersburg, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 16, 2026, 4:40 PM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT04861259
View directory record Official record
Conditions
Atypical Hemolytic Uremic Syndrome
Interventions
Crovalimab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
6
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GDC-0853 in Healthy Japanese and Caucasian Participants

NCT03188783
View directory record Official record
Conditions
Healthy Volunteer
Interventions
GDC-0853, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 1 Interventional

A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors

NCT02318394
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
MEDI0562
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
11
States / cities
La Jolla, California • Ann Arbor, Michigan • Detroit, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

Effects of the V1a Agonist FE 202158 in Patients With Septic Shock

NCT01000649
View directory record Official record
Conditions
Septic Shock
Interventions
FE 202158 1.25, FE 202158 2.5, FE 202158 3.75, Placebo
Drug · Other
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
6
States / cities
Newark, Delaware • Springfield, Massachusetts • Duluth, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity

NCT06585462
View directory record Official record
Conditions
Cardiometabolic Disease
Interventions
AMG 513, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
13
States / cities
Anaheim, California • Lake Forest, California • Oxnard, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 16, 2026, 4:40 PM EDT
Recruiting Phase 1 Interventional

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

NCT05785754
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors
Interventions
DCSZ11, Pembrolizumab, Doxorubicin, Tebentafusp
Drug
Lead sponsor
DynamiCure Biotechnology
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study

NCT01453023
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Furoate, Fluticasone Furoate/Vilanterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 11 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Huntington Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK2881078 and Study to Evaluate the Effect of CYP3A4 Inhibition on PK of GSK2881078

NCT02567773
View directory record Official record
Conditions
Cachexia
Interventions
GSK2881078, Placebo, Itraconazole
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 16, 2026, 4:40 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn More About the Safety of BIIB145 and How it is Processed in the Body of Healthy Adult Participants

NCT07225517
View directory record Official record
Conditions
Healthy Volunteer
Interventions
BIIB145, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Effect of Esomeprazole, Omeprazole or Lansoprazole on the Pharmacodynamics (PD) and Pharmacokinetics (PK) of Clopidogrel

NCT01147588
View directory record Official record
Conditions
Healthy
Interventions
lansoprazole, omeprazole, esomeprazole, clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2011 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Results available

2-Week Study In People With Nonalcoholic Fatty Liver Disease

NCT03513588
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis, Non-alcoholic Fatty Liver Disease
Interventions
Placebo, PF-06865571
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Anaheim, California • New Haven, Connecticut • South Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 4 Interventional Results available

Open-Labeled PK-PD Studies of Metoprolol ER

NCT02417246
View directory record Official record
Conditions
Blood Pressure
Interventions
brand name metoprolol ER, Generic A, Generic B
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 120 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 1 Interventional

A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT02705469
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
ZEN003694
Drug
Lead sponsor
Zenith Epigenetics
Industry
Eligibility
18 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of KPL-404 in Healthy Subjects

NCT04497662
View directory record Official record
Conditions
Healthy Volunteers
Interventions
KPL-404, Matching Placebo
Drug · Other
Lead sponsor
Kiniksa Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 16, 2026, 4:40 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Single- and Multiple-Ascending Dose Study of SRK-439 in Healthy Adults

NCT07444294
View directory record Official record
Conditions
Healthy
Interventions
Placebo, SRK-439
Drug
Lead sponsor
Scholar Rock, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 16, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Results available

A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)

NCT02493751
View directory record Official record
Conditions
Renal Cell Cancer
Interventions
Avelumab (MSB0010718C), Axitinib (AG-013736)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
12
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2022 · Synced Oct 16, 2026, 4:40 PM EDT
Recruiting Phase 1 Interventional

A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors

NCT06803680
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
BGB-B455, Chemotherapy
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Celebration, Florida • Philadelphia, Pennsylvania • Sioux Falls, South Dakota + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 16, 2026, 4:40 PM EDT